Category: Market Sharing

Precast concrete drainage cartel – appeal denied

The Competition and Markets Authority (CMA) has previously confirmed the denial of an appeal made by FP McCann Ltd, a company understood to be involved in an alleged precast concrete drainage cartel, who reportedly sought to evade the £2.5m issued to them for their reported infringement of competition law.

The earlier update with regards to the cartel investigation marks an end to the four-year legal case. It is understood that several companies had previously either admitted to their illegal practice or accepted penalties, while FP McCann lodged an appeal in December 2019 with the hope that the ruling would be overturned.

The CMA’s final decision looks to mark a victory for businesses and consumers across the UK, setting an example that any form of illegal price-fixing and collusion will not be tolerated by the watchdog.

UK roofing materials sector: updates expected soon

The investigation by the Competition and Markets Authority (CMA) that’s looking into the UK roofing materials sector remains ongoing.

We understand that more news could be issued at the end of June in-line with the current timetable in place from the CMA. So far, we have seen extensive investigations carried out over the last few years, and a formal Statement of Objections issued last year.

With an alleged cartel in place that reportedly makes up for 90% of the lead rolling market in the UK, this is a significant investigation.

More time allowed in the supply of groundworks investigation

First published by Author on November 20, 2019 in the following categories: Industry Market Sharing Price Fixing Pricing and tagged with cma | competition law | construction industry | pricing

More time has been allowed for representations to be made in the supply of groundworks investigation that’s currently being undertaken by the UK’s competition regulator.

The CMA (Compensation and Markets Authority) issued their statement of objections back in April 2019 and announced their provisional findings. The CMA confirmed that they suspect there are three suppliers who are engaging in behaviour that may distort competition in the market. Until final determinations are made, these are just allegations at this stage.

Notably, the CMA decided to continue with their investigations, so we assume that they must believe that there is some evidence to support their allegations.

Precast concrete drainage products supply investigation: latest

The CMA (Competition and Markets Authority) has issued an update in the investigation into the supply of precast concrete drainage products.

The civil investigation has been ongoing since 2016 and a number of actions and steps have been taken in the three years since it was commenced.

This month, an important development has been announced which involves fines in the tens of millions for companies who have reportedly been engaging in cartel behaviour for a number of years.

Anti-competitive agreements for pharmaceutical drugs: statement of objections issued

In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority).

The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it’s a case of formal agreements in place, or concerted practices, the issue surrounds the supply of 50mg and 100mg nitrofurantoin capsules in the UK.

This investigation by the CMA into the practices of pharmaceutical firms is one of many that have been ongoing for a number of years. They’re one of the most important areas the CMA needs to safeguard.

Provisional finding in the pharmaceuticals competition investigation

There has been a provisional finding in the pharmaceuticals competition investigation by the Competition and Markets Authority (CMA) who have been looking into companies for quite some time.

It has been alleged that anti-competitive agreements are in place between four firms in the sector, and the calculated costs to the NHS is terrifying. If the provisional finding is formalised, huge fines could be issued to the alleged offenders involved in the investigation.

The costs of anti-competitive arrangements in the pharmaceutical industry often fall on the NHS, and therefore on the taxpayer, which is why these kinds of investigations are incredibly important.

Provisional finding in the CMA roofing materials investigation

There’s been a provisional finding in the CMA roofing materials investigation that was launched in the summer of 2017, with three major suppliers alleged to be in a cartel.

The CMA (Competition and Markets Authority) believes that the three alleged cartel companies have been allocating customers, as well as information sharing and colluding on price. This type of behaviour usually only leads to one thing: bigger profits for the companies, and higher costs for the consumer.

An allegation of a cartel finding is incredibly serious, and the companies at the heart of this investigation could be issued significant fines that can run into the millions.

£7m in fines issued in office fit-out competition case

cma roofing materials sector investigations

A huge £7m in total fines has been issued after five companies have admitted to breaches in the office fit-out competition case.

The Competition and Markets Authority (CMA) has been investigating the design, construction and fit-out services market since 2017. In July 2018, they decided to continue their probes, and in March this year, fines have been issued and agreed.

The five companies that have admitted to breaches and will be fined are Coriolis, Fourfront, Loop, Oakley and ThirdWay.

Provisional finding in hydrocortisone competition case

There’s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.

In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that’s been issued.

The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.

CMA consider appeal in phenytoin competition case

First published by Author on August 17, 2018 in the following categories: Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | competition law | market abuse | price fixing | pricing

The CMA is considering an appeal in the phenytoin competition case after a Tribunal found that the CMA ruling of market abuse is incorrect.

The phenytoin competition case is one of the most pivotal cases of our time in terms of the cost of drugs to the NHS. A number of investigations and findings have been made against pharmaceutical giants for overcharging the NHS, putting huge strains on public finances, and the CMA’s intervention is vital for the survival of our public health service.

The Tribunal decision in the phenytoin competition case is a setback that the CMA is now considering an appeal for.